

Antibody-Drug Conjugates (ADCs)


What are ADCs?

Antibody-drug conjugates (ADCs) are a **precision-based** cancer therapy that combines the **targeting ability** of monoclonal antibodies with the **cell-killing** power of potent therapeutics.¹

ADCs deliver drugs **directly** to cancer cells, minimizing damage to healthy tissue and reducing side effects.^{1,2}


Structure and mechanism of action

ADCs consist of three critical components:



When an **ADC binds to its target**, it forms an **ADC-antigen complex** which is taken into the cell. The linker then **releases the payload inside**, killing the cancer cell from within.^{1,3}


ADCs in precision cancer treatment



ADCs are part of the diverse toolbox of modalities at Bristol Myers Squibb that are **matched to a molecular mechanism** of action to achieve the best possible results for patients. They are a rapidly developing and promising drug modality where recent technical progress has propelled the field forward.



ADCs have helped to **enhance the standard of care** in breast cancer and are being expanded into new, difficult-to-treat indications. These are in hematology and solid tumors, including acute myeloid leukemia, non-small cell lung cancer, ovarian cancer and endometrial cancer, among others.



They are also being explored **in combination** with other modalities, such as immunotherapies and molecularly targeted therapies, in synergistic ways to improve outcomes.

Bristol Myers Squibb is working to bring these transformational medicines to patients faster by:

- Building on a deep understanding of causal human biology to advance the science of antigen targeting to improve foundational targets and uncover new ones
- Expanding on the types of payloads delivered to cells
- Collaborating with other experts to advance the most promising ADC-enabling technology

Precision-based approaches to cancer treatment, including ADCs, have the potential to meet the needs of the many patients awaiting new, efficacious and tolerable therapies. By following the science and embracing a multifaceted approach, Bristol Myers Squibb aims to rapidly advance these transformational therapeutics to patients.

1. National Cancer Institute. (2021). Antibody-drug conjugates for cancer treatment. Retrieved from <https://www.cancer.gov/about-cancer/treatment/research/adcs>

2. National Institutes of Health. (2022). Monoclonal antibodies: Precision cancer therapy. Retrieved from <https://www.nih.gov/news-events/nih-research-matters/monoclonal-antibodies-precision-cancer-therapy>

3. U.S. Food & Drug Administration (FDA). (2020). Antibody-drug conjugates in oncology: An evolving therapeutic option. Retrieved from <https://www.fda.gov/drugs/resources-information-approved-drugs/antibody-drug-conjugates-oncology>